English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

(ctDNA) and tissue biopsy were performed. Next-generaTo the Editor: Spindle cell carcinoma (SpCC) is a rare histological type of sarcomatoid carcinoma consisting of tion sequencing revealed the harboring of a TPM3-ROS1 spindle-shaped tumorcells. SpCCcanoccur inmanydifferent organs, including the lungs. There is limited data on the clinical presentation, genetic mutant phenotype, treatment, and outcome of lung SpCC. The efficacy of molecular targeted therapy for this tumor is still unclear. Here, we report an adult male with metastatic SpCC harboring a Tropomyosin 3-ROS proto-oncogene 1 (TPM3-ROS1) fusion who showed a long-term response to targeted therapy by crizotinib, a tyrosine kinase inhibitor (TKI).

Response to crizotinib in a patient with metastatic lung spindle cell carcinoma harboring TPM3-ROS1 fusion